Sarilumab
Sarilumab is a pharmaceutical drug with 35 clinical trials. Currently 8 active trials ongoing. Historical success rate of 81.0%.
Success Metrics
Based on 17 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
18
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.3%
17 of 22 finished
22.7%
5 ended early
8
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
Clinical Trials (35)
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Sarilumab for Patients With Moderate COVID-19 Disease
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 35